Gevalka (ensartinib)

Where it stands

Gevalka (ensartinib), from SFL Pharmaceuticals Deutschland GmbH, has received a CHMP positive opinion in the EU. The opinion is dated 2026-09-17. The records show its status as "Opinion" and list no approval date, so the European Commission (EC) has not yet granted a marketing authorisation.

The indication in the opinion is the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). The therapeutic area is recorded as Carcinoma, Non-Small-Cell Lung.

The CHMP opinion is a scientific recommendation. It does not by itself authorise marketing. The EC takes the legally binding decision, normally within about 67 days of the opinion. The records give 2026-11-23 as the expected EC decision date. This is an estimate calculated as the opinion date plus 67 days, not an official date.

Regulatory pathway and designations

The records show no designations for this product. No orphan, PRIME or similar designations are recorded. The records also do not say whether the opinion covers a standard, conditional or exceptional-circumstances marketing authorisation, or whether accelerated assessment was used. This analysis therefore draws no conclusion on those points.

The procedural route is the centralised procedure, since a CHMP opinion is the step that precedes an EC decision. After a positive opinion, the Commission prepares a draft decision, consults the Member States via its standing committee, and then adopts the final decision. A decision to grant authorisation applies across the EU/EEA.

The only milestones in the records are the CHMP positive opinion (official) and the estimated EC decision (not official). Earlier steps in the procedure, such as submission and validation dates, are not covered.

Safety and pharmacovigilance

The records contain no safety data, risk management plan details, or post-authorisation commitments for Gevalka, so no safety assessment can be made here.

What to watch

The main event is the EC decision, estimated for around 2026-11-23. Treat that date as a planning estimate only. The actual date can fall earlier or later, and the records will need to show an official approval date before the product can be treated as authorised.

Once a decision is issued, the authorised indication wording should be checked against the CHMP opinion wording recorded here. The product information and any conditions attached to the authorisation will then become available. The records do not currently provide these.

For regulatory and business-development teams, the next signals to track are the official EC decision, the publication of the full product information and assessment documents, and any subsequent launch or market-access activity by SFL Pharmaceuticals Deutschland GmbH. None of these is covered in the records yet.